News
MBCOF
0.085
NaN%
--
Broadcom's Risk Is Visible, Marvell's Isn't
Seeking Alpha · 10/15 07:26
Marvell: The Hidden $15 Billion AI Opportunity Nobody Should Ignore
Seeking Alpha · 10/13 09:03
Marvell Investor Day: Connectivity Lifts Outlook To $20 Billion
Seeking Alpha · 10/08 07:45
Marvel Biosciences Reports MB-204 as Highly Effective at Treating Autism Behaviours in Shank3 Mouse Model
Barchart · 10/08 05:45
Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update
Barchart · 10/06 05:45
Marvell: The Market Is No Longer Trading On FY 2027
Seeking Alpha · 09/30 11:51
Marvel Biosciences Announces Closing of Private Placement For Up To $3.0 Million
Newsfile · 09/29 21:52
Marvel Biosciences announces non‑brokered private placement for up to $3M
Seeking Alpha · 09/17 21:29
Marvel Biosciences Provides Update on Private Placement for up to $3.0 Million
Newsfile · 09/17 21:05
Marvel Biosciences Announces Extension to Closing Date of Private Placement
Newsfile · 09/09 18:32
Marvel Biosciences Announces Grant of Deferred Share Units
Newsfile · 09/01 21:01
Marvell Technology: I Vehemently Disagree With The Market Here
Seeking Alpha · 08/31 00:17
Marvel Biosciences Reports Positive Preclinical Data Demonstrating MB-204 Reverses Behavioural and Cognitive Deficits in a Mouse Model of Fragile X
Barchart · 08/05 04:00
Marvel Biosciences launches up to C$3M private placement
Seeking Alpha · 07/16 20:04
Marvel Biosciences Announces Private Placement for up to $3.0 Million
Newsfile · 07/16 20:00
New Autism Research to be Presented at European Purine Scientific Meeting
Barchart · 06/26 06:00
Marvel Biosciences Announces Grant of Deferred Share Units
Newsfile · 05/20 11:00
Marvel Biosciences Announces Closing of Convertible Debenture Offering
Newsfile · 04/17 20:30
Marvel Biosciences lowers conversion price for proposed debenture offering
Seeking Alpha · 04/13 21:38
Marvel Biosciences Announces an Amendment to the Conversion Price for Marvel's Proposed Convertible Debenture Offering
Newsfile · 04/13 21:31
More
Webull provides a variety of real-time MBCOF stock news. You can receive the latest news about Marvel Biosciences Corp through multiple platforms. This information may help you make smarter investment decisions.
About MBCOF
Marvel Biosciences Corp. is a Canada-based pre-clinical-stage pharmaceutical development biotechnology company. The Company develops new synthetic chemical derivatives of the original approved drug for the new disease indication. It has developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs that inhibit the A2a adenosine receptor with application to neurological diseases (depression and anxiety, Alzheimer's, attention deficit hyperactivity disorder (ADHD)), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. The Company's lead compound, MB-204, is a fluorinated derivative of Istradefylline. The Company is engaged in developing MB-204 for diseases other than Parkinson's disease, specifically depression, Alzheimer’s Disease and liver fibrosis due to non-alcoholic steatohepatitis (NASH). Its wholly owned subsidiary is Marvel Biotechnology Inc.